Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RMD-009
- Development stage
- Preclinical
- Lead developer
- Remedium Technologies
- Modality
- Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
RMD-009 is an experimental gene therapy candidate being developed by Remedium Technologies for the treatment of cardiovascular diseases. It utilizes the company's proprietary Prometheus™ platform, which is designed to provide adjustable gene expression, allowing for precise control over the therapeutic protein's levels. The therapy is engineered for delivery via either Adeno-Associated Virus (AAV) or Lipid Nanoparticle (LNP) vectors. As of the current pipeline status, RMD-009 is in the Discovery and In Vivo Proof-of-Concept (POC) stages. The specific transgene and molecular target have not been publicly disclosed by the developer.
Beyond the preview
Go deeper on RMD-009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RMD-009.